AbbVie Crecimiento futuro

Future controles de criterios 4/6

AbbVie se prevé un crecimiento anual de los beneficios y los ingresos de 16.5% y 3% respectivamente. Se prevé que el BPA sea de grow en 17.6% al año. Se prevé que la rentabilidad de los fondos propios sea de 112.7% en 3 años.

Información clave

22.7%

Tasa de crecimiento de los beneficios

23.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	0%
Tasa de crecimiento de los ingresos	5.2%
Rentabilidad financiera futura	167.0%
Cobertura de analistas	Good
Última actualización	12 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

BMV:ABBV * - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	61,952	13,699	25,025	25,912	22
12/31/2025	57,801	11,379	22,646	23,772	25
12/31/2024	54,604	9,710	19,135	20,692	25
12/31/2023	54,318	4,820	22,062	22,839	N/A
9/30/2023	55,138	6,471	24,729	25,514	N/A
6/30/2023	56,023	8,635	24,799	25,542	N/A
3/31/2023	56,741	7,542	23,520	24,228	N/A
12/31/2022	58,054	11,782	24,248	24,943	N/A
9/30/2022	57,819	13,343	21,921	22,590	N/A
6/30/2022	57,349	12,569	22,214	22,923	N/A
3/31/2022	56,725	12,407	22,047	22,808	N/A
12/31/2021	56,197	11,468	21,990	22,777	N/A
9/30/2021	55,169	7,465	21,677	22,556	N/A
6/30/2021	53,729	6,599	19,572	20,451	N/A
3/31/2021	50,195	5,092	17,789	18,650	N/A
12/31/2020	45,804	4,556	16,790	17,588	N/A
9/30/2020	40,650	7,324	15,327	16,009	N/A
6/30/2020	36,227	6,906	14,115	14,734	N/A
3/31/2020	34,057	8,395	13,552	14,122	N/A
12/31/2019	33,266	7,842	12,772	13,324	N/A
9/30/2019	32,867	3,232	12,929	13,441	N/A
6/30/2019	32,624	4,093	12,770	13,410	N/A
3/31/2019	32,647	5,333	13,173	13,799	N/A
12/31/2018	32,753	5,657	12,789	13,427	N/A
9/30/2018	32,187	7,531	11,922	12,619	N/A
6/30/2018	30,946	6,419	10,825	11,366	N/A
3/31/2018	29,612	6,352	9,950	10,503	N/A
12/31/2017	28,216	5,283	9,431	9,960	N/A
9/30/2017	27,273	6,615	N/A	8,917	N/A
6/30/2017	26,710	6,582	N/A	7,100	N/A
3/31/2017	26,218	6,278	N/A	7,015	N/A
12/31/2016	25,638	5,923	N/A	7,041	N/A
9/30/2016	25,242	6,048	N/A	7,463	N/A
6/30/2016	24,754	5,690	N/A	8,164	N/A
3/31/2016	23,777	5,448	N/A	8,078	N/A
12/31/2015	22,859	5,118	N/A	7,535	N/A
9/30/2015	21,911	2,790	N/A	4,994	N/A
6/30/2015	20,986	2,064	N/A	4,625	N/A
3/31/2015	20,437	1,802	N/A	4,510	N/A
12/31/2014	19,960	1,765	N/A	3,549	N/A
9/30/2014	19,619	3,686	N/A	5,372	N/A
6/30/2014	19,258	4,144	N/A	5,384	N/A
3/31/2014	19,024	4,114	N/A	5,704	N/A
12/31/2013	18,790	4,102	N/A	6,267	N/A
9/30/2013	18,885	4,540	N/A	5,963	N/A
6/30/2013	18,735	5,161	N/A	6,414	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: ABBV *(17.3% al año) es superior a la tasa de ahorro (7.7%).

Beneficios frente mercado: ABBV *Se prevé que los beneficios de la empresa (17.3% al año) crezcan más deprisa que el mercado MX (9.2% al año).

Beneficios de alto crecimiento: ABBV *Se espera que los beneficios de la empresa crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: ABBV *(2.6% al año) se prevé que crezca más despacio que el mercado de MX (6.2% al año).

Ingresos de alto crecimiento: ABBV *Se prevé que los ingresos de la empresa (2.6% al año) crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: ABBV *Se prevé que la Rentabilidad de los fondos propios de la empresa sea muy elevada dentro de 3 años (112.7%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

AbbVie Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine

AbbVie Inc. to Report Q1, 2024 Results on Apr 26, 2024

Upcoming dividend of US$1.55 per share

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) for approximately $110 million.

AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.

AbbVie Announces U.S. Food and Drug Administration Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients

Executive VP & Chief Commercial Officer recently sold Mex$99m worth of stock

AbbVie Inc., Annual General Meeting, May 03, 2024

AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios

Chairman & CEO recently sold Mex$420m worth of stock

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

AbbVie Inc. Announces Chief Executive Officer Changes

Abbvie, Inc. Appoints Robert A. Michael as Member of the Board of Directors and Richard A. Gonzalez as Executive Chairman of the Board of Directors

Fourth quarter dividend of US$1.55 announced

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on May 15, 2024

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

AbbVie's VYALEV™? (foslevodopa/Foscarbidopa Solution) Available for the Treatment of Advanced Parkinson's Disease in Canada

AbbVie Inc. Reports Unaudited Intangible Asset Impairment for the Quarter Ended December 31, 2023

AbbVie Inc. Launches Produodopa (Foslevodopa/Foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union

Abbvie Inc. Announces Phase 2 Results Showing Adults with Moderate to Severe Hidradenitis Suppurativa

AbbVie Inc. to Report Q4, 2023 Results on Feb 02, 2024

Upcoming dividend of US$1.55 per share at 3.8% yield

Insider recently sold Mex$7.6m worth of stock

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) for $8.2 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

AbbVie Inc. Announces Positive Topline Results from Phase 2 Luminosity Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer

AbbVie Announces U.S. Food and Drug Administration and European Medicines Agency Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

AbbVie Announces Results Evaluating the Efficacy, Safety, and Tolerability of UBRELVY

Abbvie Inc. Declares Quarterly Dividend, Payable on February 15, 2024

Third quarter 2023 earnings released: EPS: US$1.00 (vs US$2.22 in 3Q 2022)

New minor risk - Profit margin trend

Lupus Therapeutics Partners with AbbVie Inc. on Clinical Trial Recruitment Efforts in SLE Through Lucin Lupus Clinical Trial Network

Abbvie Inc. Epkinly™ (Epcoritamab Injection/Epcoritamab for Injection) Receives Health Canada Authorization with Conditions as the First and Only Subcutaneous Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl)

AbbVie Presents Positive Results from Head-to-Head Phase 3 Sequence Study in Crohn's Disease Meets All Primary and Secondary Endpoints

AbbVie Inc. Announces Director Appointments

AbbVie Inc. Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (Upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis

AbbVie Inc. (NYSE:ABBV) acquired Mitokinin, Inc. for $655 million.

AbbVie Inc. to Report Q3, 2023 Results on Oct 27, 2023

Upcoming dividend of US$1.48 per share at 4.0% yield

Abbvie Presents Results from Phase 3 Canova Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

AbbVie Announces European Commission Approval of TEPKINLY (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Abbvie Inc. Announces Top-Line Results from the Phase 3 Sequence Clinical Trial Evaluating Risankizumab

AbbVie Inc. Declares Quarterly Dividend, Payable on November 15, 2023

AbbVie Inc. Submits Regulatory Applications to FDA and Ema for Risankizumab (Skyrizi®) in Ulcerative Colitis

Abbvie Inc. Announces European Commission Approves AQUIPTA for the Prophylaxis of Migraine in Adults

Chairman & CEO recently sold Mex$197m worth of stock

Second quarter 2023 earnings released: EPS: US$1.14 (vs US$0.52 in 2Q 2022)

AbbVie Announces the British Journal of Dermatology Publishes Results from the Head-To-Head Phase 4 IMMpulse Study

Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

New major risk - Share price stability

AbbVie Inc. to Report Q2, 2023 Results on Jul 27, 2023

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento